SCHEMBL1659848

SCHEMBL1659848

O=C(C=Cc1ccc(O)c(O)c1)OCC=Cc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 5/20 0.67
AKR1B10 O60218 2/20 0.67
AKR1B1 P15121 2/20 0.67
APP P05067 11/20 0.67
CYP3A4 P08684 2/20 0.64
ALOX15 P16050 2/20 0.64
ALOX12 P18054 2/20 0.64
MAPK1 P28482 2/20 0.64
HSD17B10 Q99714 2/20 0.64
ALDH1A1 P00352 2/20 0.64
MAPT P10636 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
ALOX5 P09917 2/20 0.64
KDM4E B2RXH2 1/20 0.64
MEN1 O00255 1/20 0.64
GMNN O75496 1/20 0.64
EGFR P00533 1/20 0.64
LMNA P02545 1/20 0.64
ESR1 P03372 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30448962 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL30610038 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20914983 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL30431823 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20914982 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL25199144 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20914984 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20941431 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL20914981 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4
SCHEMBL30449303 1.00 TTR (0.67) TTRAKR1B10AKR1B1APPCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3169321-B1 PROPOLIS AND EXTRACTS THEREOF FOR THE TREATMENT OF SKIN CANCERS AND IMPROVEMENT OF SKIN HEALTH MANUKA HEALTH NEW ZEALAND LTD (NZ) 2020-07-15 EP claimed
US-20170209499-A1 Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health MANUKA HEALTH NEW ZEALAND LIMITED (NZ) 2017-07-27 US claimed
EP-3169321-A1 PROPOLIS AND EXTRACTS THEREOF FOR THE TREATMENT OF SKIN CANCERS AND IMPROVEMENT OF SKIN HEALTH Manuka Health New Zealand Limited (NZ) 2017-05-24 EP claimed
WO-2016010440-A1 PROPOLIS AND EXTRACTS THEREOF FOR THE TREATMENT OF SKIN CANCERS AND IMPROVEMENT OF SKIN HEALTH MANUKA HEALTH NEW ZEALAND LIMITED (NZ) 2016-01-21 WO claimed
US-20240389587-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) 2024-11-28 US disclosed
EP-4440313-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS Institut national de recherche pour l'agriculture, L'alimentation et l'environnement (INRAE) (FR) 2024-10-09 EP disclosed
CN-118714927-A Compositions and methods for controlling phytopathogenic infection 法国国家农业食品与环境研究院 2024-09-27 CN disclosed
WO-2023099609-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) 2023-06-08 WO disclosed
EP-4186367-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE) (FR) 2023-05-31 EP disclosed
CN-112569219-B Medicine for treating artery related diseases and application thereof 中国科学院上海药物研究所 2023-05-02 CN disclosed
US-20220395476-A1 DRUG FOR TREATING ARTERY-RELATED DISEASES, AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2022-12-15 US disclosed
EP-4043012-A1 DRUG FOR TREATING ARTERY-RELATED DISEASES, AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2022-08-17 EP disclosed
WO-2016010440-A1 PROPOLIS AND EXTRACTS THEREOF FOR THE TREATMENT OF SKIN CANCERS AND IMPROVEMENT OF SKIN HEALTH MANUKA HEALTH NEW ZEALAND LIMITED (NZ) 2016-01-21 WO disclosed
US-20150246014-A1 Derivatives of Propane Diyl Dicinnamate ORX PHARMACEUTICAL CORPORATION (CA) 2015-09-03 US disclosed
US-9061993-B2 Derivatives of propane diyl dicinnamate Toronto Institute of Pharmaceutical Technology (CA) 2015-06-23 US disclosed
WO-2014163512-A1 THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF MANUKA HEALTH NEW ZEALAND LIMITED (NZ) 2014-10-09 WO disclosed
EP-2486026-A1 DERIVATIVES OF DI(PHENYLPROPANOID) GLYCEROL FOR THE TREATMENT OF CANCER MacGregor, Alexander (CA) 2012-08-15 EP disclosed
CN-102264713-A Di (phenylpropanoid) glycerol derivatives for the treatment of cancer 2011-11-30 CN disclosed
WO-2011041907-A1 DERIVATIVES OF DI(PHENYLPROPANOID) GLYCEROL FOR THE TREATMENT OF CANCER MACGREGOR ALEXANDER (CA) 2011-04-14 WO disclosed
US-20110086912-A1 Derivatives of Propane Diyl Dicinnamate MACGREGOR ALEXANDER 2011-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246014-A1 Derivatives of Propane Diyl Dicinnamate H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DECR2, DECR1 TTR 3354/4885AKR1B10 127/4885AKR1B1 84/4885
US-20220395476-A1 DRUG FOR TREATING ARTERY-RELATED DISEASES, AND USE THEREOF MYLK, AGT, TNNI3 TTR 1508/4885AKR1B10 210/4885AKR1B1 159/4885
US-20170209499-A1 Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health CUTA, DSC1, DACH1 TTR 2239/4885AKR1B10 2559/4885AKR1B1 3052/4885
US-20110086912-A1 Derivatives of Propane Diyl Dicinnamate H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DECR2, DECR1 TTR 3318/4885AKR1B10 137/4885AKR1B1 88/4885
US-20240389587-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS XBP1, ERN1, ERN2 TTR 3033/4885AKR1B10 2183/4885AKR1B1 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.